



**HAL**  
open science

## Live intramacrophagic *Staphylococcus aureus* as a potential cause of antibiotic therapy failure observations in an in vivo mouse model of prosthetic vascular material infections

Rym Boudjemaa, Karine Steenkeste, Cédric Jacqueline, Romain Briandet, Jocelyne Caillon, David Boutilie, Virginie Le Mabecque, Pierre Tattevin, Marie-Pierre Fontaine-Aupart, Matthieu Revest

### ► To cite this version:

Rym Boudjemaa, Karine Steenkeste, Cédric Jacqueline, Romain Briandet, Jocelyne Caillon, et al.. Live intramacrophagic *Staphylococcus aureus* as a potential cause of antibiotic therapy failure observations in an in vivo mouse model of prosthetic vascular material infections. *Journal of Antimicrobial Chemotherapy*, 2018, 73 (1), pp.2418-2421. 10.1093/jac/dky205 . hal-01834453v1

**HAL Id: hal-01834453**

**<https://univ-rennes.hal.science/hal-01834453v1>**

Submitted on 3 Sep 2018 (v1), last revised 6 Sep 2018 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Live intramacrophagic *Staphylococcus aureus* as potential responsible for antibiotic therapy  
2 failure: observations in an *in-vivo* mouse model of prosthetic vascular material infections

3

4 Rym Boudjema<sup>1</sup>, Karine Steenkeste<sup>1</sup>, Cédric Jacqueline<sup>2</sup>, Romain Briandet<sup>3</sup>, Jocelyne  
5 Caillon<sup>2</sup>, David Boutoille<sup>2</sup>, Virginie Le Mabecque<sup>2</sup>, Pierre Tattevin<sup>4,5</sup>, Marie-Pierre Fontaine-  
6 Aupart<sup>1</sup>, Matthieu Revest<sup>2,4,5\*</sup>

7

8 <sup>1</sup>Institut des Sciences Moléculaires d'Orsay (ISMO), CNRS, Univ. Paris-Sud, Université  
9 Paris-Saclay, F-91405 Orsay, France

10 <sup>2</sup>EA 3826, Université Nantes, Faculté Médecine EA3826 Nantes, France

11 <sup>3</sup>Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 Jouy-en-Josas,  
12 France

13 <sup>4</sup>Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033 Rennes,  
14 France

15 <sup>5</sup>Univ Rennes, Inserm, U1230, F-35000 Rennes, France

16

17

18

19

20

21

22

23

24

25

1 **Authors list :**

2 Rym BOUDJEMAA : Institut des Sciences Moléculaires d'Orsay (ISMO), CNRS, Univ.

3 Paris-Sud, Université Paris-Saclay, F-91405 Orsay, France

4 Karine STEENKESTE : Institut des Sciences Moléculaires d'Orsay (ISMO), CNRS, Univ.

5 Paris-Sud, Université Paris-Saclay, F-91405 Orsay, France

6 Cédric JACQUELINE : EA 3826, Université Nantes, Faculté Médecine EA3826 Nantes,

7 France

8 Romain BRIANDET : Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay,

9 78350 Jouy-en-Josas, France

10 Jocelyne CAILLON : EA 3826, Université Nantes, Faculté Médecine EA3826 Nantes, France

11 David BOUTOILLE : EA 3826, Université Nantes, Faculté Médecine EA3826 Nantes,

12 France

13 Virginie LE MABECQUE : EA 3826, Université Nantes, Faculté Médecine EA3826 Nantes,

14 France

15 Pierre TATTEVIN : Service des Maladies Infectieuses et Réanimation Médicale, CHU

16 Rennes, 35033 Rennes, France ; Univ Rennes, Inserm, U1230, F-35000 Rennes, France

17 Marie-Pierre FONTAINE-AUPART : Institut des Sciences Moléculaires d'Orsay (ISMO),

18 CNRS, Univ. Paris-Sud, Université Paris-Saclay, F-91405 Orsay, France

19 Matthieu REVEST\* : EA 3826, Université Nantes, Faculté Médecine EA3826 Nantes,

20 France ; Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033

21 Rennes, France ; Univ Rennes, Inserm, U1230, F-35000 Rennes, France

22

23

24

25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**Correspondig author :**

Prof Matthieu REVEST, current affiliation : Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033 Rennes, France ; Univ Rennes, Inserm, U1230, F-35000 Rennes, France

Phone : +33 2 99 28 95 64

Fax : +33 2 99 28 94 64

e-mail : [matthieu.revest@chu-rennes.fr](mailto:matthieu.revest@chu-rennes.fr)

**Running Title**

Intramacrophagic *Staphylococcus aureus* in vascular infection

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

**ABSTRACT**

Objective: evaluating the significant role played by biofilms during prosthetic vascular material infections (PVMIs). Methods: we developed an *in-vivo* mouse model of *Staphylococcus aureus* PVMI allowing its direct observation by confocal microscopy to describe: (i) the structure of biofilms developed onto a Dacron<sup>®</sup> vascular material, (ii) the localization and the effect of antibiotics on these biostructures and (iii) the interaction between bacteria and host tissues and cells during PVMI. Results: in this model, we highlight that the biofilms structures are correlated to the activity of antibiotics. Furthermore, live *S. aureus* bacteria were visualized inside the macrophages present at the biofilm sites while antibiotics do not penetrate in these immune cells. Conclusion: this intracellular situation could represent one explanation of the only limited effect of antibiotics but also of the possibility of PVMIs relapse after antibiotic therapy.

## 1 **Introduction**

2 *Staphylococcus aureus* biofilm development plays a significant role in the difficulties  
3 encountered when treating prosthetic vascular material infections (PVMIs). Previous literature  
4 data provided evidence that *S. aureus*, classically considered as an extracellular pathogen, can  
5 also invade and survive inside immune cells, including the phagocytic cells. Such survival  
6 mechanism could be responsible for the lack of antibiotics efficiency and the possibility of  
7 relapse of chronic infections.<sup>1</sup> This hypothesis was suggested from *in vitro* co-culture models  
8 and data reporting such *in vivo* interactions between *S. aureus* and mammalian tissues in the  
9 particular setting of PVMIs are scarce.

10 We recently developed an *in-vivo* mouse model of *S. aureus* PVMI evaluating the efficacy of  
11 different antibiotic regimen on six clinical and collection *S. aureus* strains.<sup>2</sup> While antibiotics  
12 MICs were similar for all strains, their antibacterial efficacy was overall limited and strain-  
13 dependent. For instance, mice infected with Methicillin-Resistant *S. aureus* (MRSA) BCB8  
14 were cured with daptomycin monotherapy while this antibiotic demonstrated no efficacy for  
15 Methicillin-Susceptible *S. aureus* (MSSA) ATCC 27217. To better understand these  
16 surprising results, we used the same PVMI model to visualize *in situ* the *S. aureus* biofilms  
17 structures whether treated or not with antibiotics. In particular, we focused on the interaction  
18 between immune cells and bacteria embedded in biofilms to address whether intracellular  
19 position of *S. aureus* could be an explanation of the lack of antibiotic efficacy in PVMIs.

20

## 21 **Materials and methods**

22 Based on our previous data<sup>2</sup> on six *S. aureus* clinical and collection strains, we selected the  
23 two most representative bacterial strains: one Methicillin-Susceptible *S. aureus* (MSSA)  
24 ATCC 27217 and one Methicillin-Resistant *S. aureus* (MRSA) BCB8 isolated from blood  
25 cultures. Both strains were fully sensitive to the antibiotics tested (MIC were: daptomycin =

1 0.125 mg/L for MRSA and 0.25 mg/L MSSA, vancomycin = 1 mg/L for both strains and  
2 rifampicin <0.006 mg/L for both strains). Antistaphylococcal agents were provided by drug  
3 companies and prepared following label instructions: vancomycin (Sandoz, Levallois-Perret,  
4 France), daptomycin (Novartis Pharma SAS, Rueil-Malmaison, France) and rifampicin  
5 (Sanofi-Aventis, Paris, France). The *in-vivo* experiments were approved by the French  
6 ministry of research review board and have been described elsewhere.<sup>2</sup> Briefly, at least 4  
7 Four-weeks old female Swiss mice (RjOrl/SWISS, Janvier laboratory St Berthevin, France)  
8 were used for the experiments. Sterile squares of Dacron<sup>®</sup> were implanted into a subcutaneous  
9 pocket created in the centre of the mice back after general anaesthesia. Two days later, a  
10 saline solution containing  $10^7$  colony forming units (cfu) of *S. aureus* was transcutaneously  
11 inoculated onto the graft surface. Antibiotics treatment started two days later. All the  
12 antibiotics used were administered at dose regimens resulting in serum concentrations similar  
13 to those obtained in humans and through the respective classical routes used in mice model.  
14 Mice were randomized into different groups: no treatment (controls); vancomycin group  
15 (subcutaneous injection (SC), 110 mg/kg/12 h);<sup>3</sup> daptomycin group (50 mg/kg/24 h, SC);<sup>4</sup>  
16 rifampicin group (30 mg/kg/12 h, intraperitoneal);<sup>5</sup> vancomycin-rifampicin group; and  
17 daptomycin-rifampicin group. Mice were treated for 48 h and then euthanized following  
18 international guidelines. Immediately after the procedure, Dacron<sup>®</sup> patches were removed and  
19 visualized with a confocal laser scanning microscope (Leica TCS SP5 Microsystems, France).  
20 Images were acquired using a  $\times 63$  oil immersion objective with a numerical aperture of 1.4.  
21 For all the experiments, the size of the confocal images was 512 x 512 pixels (either 215 by  
22 215  $\mu\text{m}^2$  or 82 by 82  $\mu\text{m}^2$ ), recorded with a z-step of 1  $\mu\text{m}$  and a 3x zoom. For each biofilm, at  
23 least four different regions were analysed and biofilms structures were compared by direct  
24 observation. For this purpose, nucleic acids (both bacteria and eukaryotic cells) were stained  
25 with Syto9<sup>®</sup> (Invitrogen), able to penetrate into all cells, and propidium iodide (PI,

1 Invitrogen), which can only penetrate into damaged-membrane cells. Syto9® and PI were  
2 excited with an Argon laser at 488 and 543 nm, respectively, and their fluorescence emissions  
3 were collected between 500-600 nm for Syto9® and between 640-750 nm for PI.  
4 To visualize simultaneously the bacteria, the immune cells (neutrophils and macrophages),  
5 and the antibiotics, all were specifically stained to well discriminate their fluorescence  
6 emission. Neutrophils were stained with Ly-6G®/mouse specific marker (GR-1, Pacific  
7 Blue™ conjugate RB6-8C5), excited using Argon laser at 361 nm; the fluorescence emission  
8 was collected in the range 400-450 nm). Macrophages were stained with F4/80® macrophage-  
9 specific antibody (Alexa Fluor® 647 conjugate BM8), excited with a Neon laser at 633 nm;  
10 the fluorescence emission was collected in the range 650-750 nm. BODIPY-FL®-daptomycin  
11 (kindly provided by Cubist Pharmaceuticals) and BODIPY-FL®-vancomycin (from Sigma)  
12 were excited at 488 nm and the fluorescence emission was collected in the range 500-550 nm.

13

## 14 **Results**

15 Typical structures of *in vivo* MSSA and MRSA-infected Dacron® patches were illustrated in  
16 Figure 1. As expected for an infection site, high amounts of bacteria and immune cells were  
17 trapped in a dense and thick reticular extracellular matrix (Figure 1, A, B). We can also note  
18 that there are only few amounts of damaged cells after Dacron removal from mice. When  
19 antibiotics were applied, the observed structures were antibiotic- and strain-dependent. In the  
20 case of antibiotics inefficiency, the visualization of Dacron® patches was very similar to the  
21 controls (Figure 1, E,F,I,L). By contrast, the material surface displayed lightened structures  
22 with only scattered immune cells when antibiotics were efficient (Figure 1, C,D,G,H,J,K). In  
23 more details, for MRSA BCB8, vancomycin did not show any significant effect on biofilms  
24 compared to the control samples by contrast to rifampicin and daptomycin. For MSSA 27217,  
25 the effect of daptomycin as well as vancomycin was more limited, yielding bacterial



1 structures close to the control ones while rifampicin was the most active. The combination of  
2 rifampicin to vancomycin appeared as very efficient in the overall structure lightening, which  
3 was not the case for the daptomycin-rifampicin combination. These results all correlate with  
4 bactericidal activity measurements (Table S1).<sup>2</sup>

5 Additional observations were obtained with the fluorescent staining of immune cells and  
6 antibiotics, highlighting that: (i) the eukaryotic cells on the infection site were essentially  
7 polynuclears and macrophages (Figure 2A), (ii) live *S. aureus* bacteria were found inside both  
8 live and dead macrophages (Figure 2B) but not in polynuclear cells, and (iii) BODIPY-  
9 vancomycin and – daptomycin were visualized in polynuclear cells but none of them  
10 penetrated macrophages load with live *S. aureus* bacteria (Figure 2C).

11

## 12 **Discussion**

13 The visualization of antibiotics within biofilm-associated bacteria may contribute to our  
14 understanding of the differential effects of antistaphylococcal agents on material-associated *S.*  
15 *aureus* infections and that was the purpose of the present study. Dacron<sup>®</sup> implants where  
16 biofilms grown in alive mice were visualized by confocal fluorescence microscopy  
17 immediately after mice were euthanized. This procedure allowed: i) to observe *in situ* live  
18 bacteria interactions with the prosthetic vascular material but also with the host cells  
19 (polynuclear cells and macrophages), widely present on the infection site, ii) to correlate the  
20 biofilms structures with antibacterial activity of antibiotics (daptomycin, vancomycin and  
21 their association with rifampicin), iii) to highlight live *S. aureus* bacteria inside the  
22 macrophages present at the biofilm sites while antibiotics do not penetrate these immune  
23 cells.

24 These *in vivo* results are different from the ones found in *in-vitro* biofilm models<sup>6</sup> that do not  
25 allow to observe the interactions between bacteria and host-cells occurring *in-vivo*.<sup>7</sup> Most *in-*

1 *in vivo* models rely on bacterial counts within infected materials, but do not include imaging  
2 techniques visualizing the direct effect of antibiotics on biofilms developed *in-vivo*.<sup>8</sup> The *S.*  
3 *aureus* PVMI mouse model presented herein may provide original data in this field.

4 Our results do not reveal significant change in the biofilms structures from one *S. aureus*  
5 isolate to another but a differential effect of antistaphylococcal agents. We confirm the  
6 dramatic efficacy of rifampicin by comparison with other treatments,<sup>8,9,10</sup> probably due to its  
7 well-known great intracellular penetration and activity. Unexpectedly, daptomycin, often  
8 referred as one of the most active antistaphylococcal agent on biofilm,<sup>11 12</sup> can yield to very  
9 limited effects. The antibiotic was active on MRSA BCB8-related biofilm onto Dacron<sup>®</sup> but  
10 not for MSSA 27217 biofilm. These results support previous findings showing that there is no  
11 difference between vancomycin and daptomycin activities *in-vitro*<sup>13</sup> or *in-vivo*.<sup>14</sup> We do not  
12 have a definitive explanation for such differences of daptomycin efficacy according to the  
13 staphylococcal strain but we already reported in an *in-vitro* model<sup>15</sup> that tolerance toward this  
14 molecule may be related to a physiological change involving structural modifications of the  
15 membrane, a strain-dependent process.

16 Previous literature findings have reported the capability of *S. aureus* to survive within  
17 osteoblasts in the context of bone and joint infections, resulting in persistent and relapsing  
18 infections.<sup>16</sup> We visualize here the same possible capacity to survive inside host cells (i.e.,  
19 macrophages) during *S. aureus* PVMI. An important consequence of such process is that  
20 intramacrophagic *S. aureus* are able to escape the phagolysosome, leading to free replication  
21 in the cytoplasm. This can trigger cell death mechanisms from its host cell, multiply actively  
22 and disseminate, but also activate anti-apoptotic programs to persist hidden in intracellular  
23 position and induce chronic or relapsing infections.<sup>1</sup> In addition, intramacrophagic position  
24 could represent a shelter for *S. aureus* against antibiotics: the less able to penetrate host  
25 eukaryotic cells they are, the less efficient they could be.

1 Thus, we hypothesize that the persistence of *S. aureus* inside macrophage during PVMIs  
2 could be an explanation to the relative inefficacy of antibiotics without surgery during these  
3 infections, and to the high risk of relapse when the infected material is not removed. This  
4 could also explain why antibiotic efficacy could be different according to the strain involved,  
5 since the capability of *S. aureus* to invade mammalian cells could vary from one strain to  
6 another.<sup>17</sup>

7 This study presents some limitations. First, the site of vascular prosthetic material  
8 implantation. For evident technical reasons, it was impossible to implant our Dacron<sup>®</sup> along  
9 the vascular system. Some authors already described extra-anatomic animal model, with  
10 implantation of vascular material in subcutaneous position, to evaluate different prophylactic  
11 procedure to prevent PVMIs.<sup>18</sup> Nevertheless, in a clinical setting, most PVMIs occur from the  
12 wound or from an adjacent infectious focus and not through hematogenous route.<sup>19</sup> Therefore,  
13 the infection process usually starts along the external part of the vascular prosthesis, not the  
14 endoluminal layer. In this context, our model reproduces this natural history of infection and  
15 may be reasonably used to evaluate different antibiotic regimens for PVMIs treatment.

16 The limited number of evaluated bacterial strains could be a second weakness of our work.  
17 This study follows a previous published work<sup>2</sup> dealing with the antibiotics activity on six  
18 different *S. aureus* strains in our mouse model of PVMI. Similar results were obtained for  
19 MSSA or MRSA strains and thus, we selected the two more representative bacterial strains to  
20 allow more demonstrative differences in the aspect of *in-vivo* biofilm developed onto Dacron<sup>®</sup>  
21 upon antibiotics action.

22 In conclusion, this *in-vivo* mouse model of *S. aureus* PVMIs allows the direct observation of  
23 the impact of major antistaphylococcal agents on Dacron<sup>®</sup>-related biofilm. We visualized  
24 intramacrophagic *S. aureus* onto the biomaterial and we hypothesize that intramacrophagic *S.*  
25 *aureus* could be also present during PVMIs in clinical settings and may explain why bacteria

1 may persist, and relapse, even after prolonged and appropriate antibacterial therapy. More  
2 studies are needed, but we can postulate that the use of antibiotics active against biofilm-  
3 embedded and intracellular bacteria such as rifampicin could be a very good option in PVMIs.

4

## 5 **Acknowledgements**

6 The authors want to acknowledge the Collège des enseignants des Maladies Infectieuses et  
7 Tropicales (CMIT) and the Société Française de Pathologie Infectieuse de Langue Française  
8 (SPILF) for their support. They also want to acknowledge Prof. Erwan Flecher who kindly  
9 provided the Dacron<sup>®</sup>.

10

## 11 **Funding**

12 This work was support by a grant from the Collège des enseignants des Maladies Infectieuses  
13 et Tropicales and by a grant from the Ministère de l'Education Nationale et de la Recherche,  
14 Université Paris-Sud, for the PhD thesis (grant n° 2014-172)

15

## 16 **Transparency declarations**

17 Nothing to declare


18

## 1 References

- 2
- 3 1. Fraunholz M, Sinha B. Intracellular *Staphylococcus aureus*: live-in and let die. *Front in*
- 4 *Cell Infect Microbiol* 2012; **2**: 43.
- 5 2. Revest M, Jacqueline C, Boudjemaa R *et al.* New *in vitro* and *in vivo* models to
- 6 evaluate antibiotic efficacy in *Staphylococcus aureus* prosthetic vascular graft infection. *J*
- 7 *Antimicrob Chemother* 2016; **71**: 1291-9.
- 8 3. Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures
- 9 of telavancin and vancomycin against methicillin-resistant *Staphylococcus aureus* with a
- 10 range of vancomycin MICs in a murine pneumonia model. *Antimicrob Agents Chemother*
- 11 2010; **54**: 5115-9.
- 12 4. Dandekar PK, Tessier PR, Williams P *et al.* Pharmacodynamic profile of daptomycin
- 13 against Enterococcus species and methicillin-resistant *Staphylococcus aureus* in a murine
- 14 thigh infection model. *J Antimicrob Chemother* 2003; **52**: 405-11.
- 15 5. Yu J, Wu J, Francis KP *et al.* Monitoring *in vivo* fitness of rifampicin-resistant
- 16 *Staphylococcus aureus* mutants in a mouse biofilm infection model. *J Antimicrob Chemother*
- 17 2005; **55**: 528-34.
- 18 6. Abdelhady W, Bayer AS, Seidl K *et al.* Impact of vancomycin on sarA-mediated biofilm
- 19 formation: role in persistent endovascular infections due to methicillin-resistant
- 20 *Staphylococcus aureus*. *J Infect Dis* 2014; **209**: 1231-40.
- 21 7. Bjarnsholt T, Alhede M, Alhede M *et al.* The *in vivo* biofilm. *Trends Microbiol* 2013;
- 22 **21**: 466-74.
- 23 8. Nishitani K, Sutipornpalangkul W, de Mesy Bentley KL *et al.* Quantifying the natural
- 24 history of biofilm formation *in vivo* during the establishment of chronic implant-associated
- 25 *Staphylococcus aureus* osteomyelitis in mice to identify critical pathogen and host factors. *J*
- 26 *Orthop Res* 2015; **33**: 1311-9.
- 27 9. Edmiston CE, Jr., Goheen MP, Seabrook GR *et al.* Impact of selective antimicrobial
- 28 agents on staphylococcal adherence to biomedical devices. *Am J Surg* 2006; **192**: 344-54.
- 29 10. Senneville E, Joulie D, Legout L *et al.* Outcome and predictors of treatment failure in
- 30 total hip/knee prosthetic joint infections due to *Staphylococcus aureus*. *Clin Infect Dis* 2011;
- 31 **53**: 334-40.
- 32 11. Stewart PS, Davison WM, Steenbergen JN. Daptomycin rapidly penetrates a
- 33 *Staphylococcus epidermidis* biofilm. *Antimicrob Agents Chemother* 2009; **53**: 3505-7.
- 34 12. Murillo O, Garrigos C, Pachon ME *et al.* Efficacy of high doses of daptomycin *versus*
- 35 alternative therapies against experimental foreign-body infection by methicillin-resistant
- 36 *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2009; **53**: 4252-7.
- 37 13. Smith K, Perez A, Ramage G *et al.* Comparison of biofilm-associated cell survival
- 38 following *in vitro* exposure of methicillin-resistant *Staphylococcus aureus* biofilms to the
- 39 antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. *Int J Antimicrob*
- 40 *Agents* 2009; **33**: 374-8.
- 41 14. Lefebvre M, Jacqueline C, Amador G *et al.* Efficacy of daptomycin combined with
- 42 rifampicin for the treatment of experimental methicillin-resistant *Staphylococcus aureus*
- 43 (MRSA) acute osteomyelitis. *Int J Antimicrob Agents* 2010; **36**: 542-4.
- 44 15. Boudjemaa R, Briandet R, Revest M, *et al.* New insight into daptomycin bioavailability
- 45 and localization in *Staphylococcus aureus* biofilms by dynamic fluorescence imaging.
- 46 *Antimicrob Agents Chemother* 2016; **60**: 4983-90.


- 1 16. Valour F, Rasigade JP, Trouillet-Assant S *et al.* Delta-toxin production deficiency in  
2 *Staphylococcus aureus*: a diagnostic marker of bone and joint infection chronicity linked with  
3 osteoblast invasion and biofilm formation. *Clin Microbiol Infect* 2015; **21**: 568 e1- e11.
- 4 17. Scherr TD, Hanke ML, Huang O *et al.* *Staphylococcus aureus* Biofilms Induce  
5 Macrophage Dysfunction Through Leukocidin AB and Alpha-Toxin. *mBio* 2015; **6**.
- 6 18. Cirioni O, Mocchegiani F, Ghiselli R *et al.* Daptomycin and rifampin alone and in  
7 combination prevent vascular graft biofilm formation and emergence of antibiotic resistance  
8 in a subcutaneous rat pouch model of staphylococcal infection. *Eur J Vasc Endovasc* 2010;  
9 **40**: 817-22.
- 10 19. Jones L, Braithwaite BD, Davies B *et al.* Mechanism of late prosthetic vascular graft  
11 infection. *Cardiovasc Surg* 1997; **5**: 486-9.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47



1  
2  
3 **Figure 1: The structures of biofilms developed on Dacron® *in vivo* are antibiotic-**  
4 **dependent.** Visualization of Dacron®-related *S. aureus* biofilms depending on antibiotics  
5 treatments by confocal laser scanning microscopy. A and B: controls, C and D: daptomycin, E  
6 and F: vancomycin, G and H: rifampicin, I and J: daptomycin-rifampicin, K and L: vancomycin-  
7 rifampicin.

8 Green staining: Syto9® (live cells), red staining: Propidium Iodide (membrane-damaged  
9 cells). White arrows: reticular structures corresponding to the extracellular matrix. Red  
10 arrows: single bacteria included within this structure. Blue arrows: eukaryotic cells. Yellow  
11 arrows: intracellular *S. aureus*.



15  
16  
17 **Figure 2: *S. aureus* bacteria are localized in macrophages that daptomycin and vancomycin**  
18 **cannot penetrate.**

19 **A:** identification of eukaryotic cells. Green staining: Syto9®; Blue staining: Ly6G® (neutrophil  
20 polynuclear specific staining); Red staining: F4/80 (macrophages specific staining). Yellow  
21 arrow: intramacrophagic live *S. aureus* (observed on biofilms treated or not with vancomycin  
22 and daptomycin).

23 **B:** antibiotic staining. Yellow staining: BODIPY-FL-vancomycin or -daptomycin; Blue staining:  
24 Ly6G® (neutrophil polynuclear specific staining); Red staining: F4/80 (macrophages specific  
25 staining).

26  
27  
28  
29